19 recruiting, 15 completed, 4 terminated, 2 active not recruiting. 45 Phase 2, 12 Phase 1, 6 Phase 3.
Follow Malignant Neoplasm: new trials by email Literature Review of Malignant Neoplasm trials Research Report on Malignant Neoplasm
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| A Clinical Trial of MK-2750 in Participants With Advanced Solid Tumors (MK-2750-002) MK-2750, 5-HT3 serotonin receptor antagonist, NK-1 receptor antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Not yet recruiting | Merck Sharp & Dohme LLC | 300 | 2026-11-16 | 2026-10-15 |
| Nasal Inhalation of Isopropyl Alcohol for the Treatment of Nausea in Patients With Cancer Isopropyl Alcohol, Placebo, Questionnaire Administration - Malignant Neoplasm | Phase 2 | Not yet recruiting | M.D. Anderson Cancer Center | 112 | 2026-11-05 | 2026-05-27 |
| A Study of Belzutifan in Adolescent Participants With Solid Tumors (MK-9999-01E/LIGHTBEAM-U01) Belzutifan - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 15 | 2026-10-13 | 2026-11-10 |
| A Clinical Trial of MK-2010 With Sacituzumab Tirumotecan (Sac-TMT) in Participants With Solid Tumors (MK-2010) MK-2010, Sacituzumab tirumotecan, Histamine H1 Receptor Antagonist - Advanced Solid Tumors, Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 200 | 2026-10-07 | 2026-10-15 |
| A Study of Ifinatamab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01D/LIGHTBEAM-U01) Ifinatamab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 134 | 2026-07-06 | 2026-10-30 |
| A Study of Pembrolizumab in Japanese Pediatric Participants With Solid Tumors or Lymphomas and Japanese Adult Participants With Merkel Cell Carcinoma (MK-3475-G21/KEYNOTE-G21) Pembrolizumab - Malignant Neoplasm, Carcinoma, Merkel Cell | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 20 | 2026-06-23 | 2026-07-13 |
| DETERMINE Trial Treatment Arm 07: Dabrafenib in Combination With Trametinib in Adult, Paediatric and Teenage/Young Adult Patients With BRAF V600 Mutation-Positive Cancers. Dabrafenib, Trametinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2026-04-01 | 2026-08-17 |
| KEYMAKER-U01 Substudy 01J: A Study of Pembrolizumab Plus MK-1084 in Participants With Non-Small Cell Lung Cancer (NSCLC) With Kirsten Rat Sarcoma Viral Oncogene Homolog (KRAS) G12C Mutations (MK-3475-01J/KEYMAKER-U01J) MK-1084, Pembrolizumab, Cetuximab - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 140 | 2025-12-19 | 2026-11-10 |
| DETERMINE Trial Treatment Arm 03: Entrectinib in Adult, Paediatric and Teenage/Young Adult Patients With ROS1 Gene Fusion-Positive Cancers. Entrectinib - Haematological Malignancy, Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2025-11-30 | 2025-11-24 |
| A Study of MK-5684 in People With Certain Solid Tumors (MK-5684-015/OMAHA-015) Opevesostat, Fludrocortisone/ Fludrocortisone acetate, Dexamethasone/Dexamethasone acetate - Malignant Neoplasm | Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 250 | 2025-08-11 | 2026-10-06 |
| A Study of Patritumab Deruxtecan in Pediatric Participants With Relapsed or Refractory Solid Tumors (MK-9999-01C/LIGHTBEAM-U01) Patritumab Deruxtecan - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 50 | 2025-05-26 | 2026-10-06 |
| A Study to Evaluate the Safety and Efficacy of MK-3120 in Participants With Advanced Solid Tumors (MK-3120-002) MK-3120 - Advanced Solid Tumors, Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Merck Sharp & Dohme LLC | 270 | 2025-03-25 | 2026-11-10 |
| DETERMINE Trial Treatment Arm 06: Capmatinib in Adult Patients With Cancers Harbouring MET Dysregulations Capmatinib - Solid Tumour, Haematological Malignancy | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2024-11-19 | 2025-11-24 |
| A Study of TSN1611 Treating Patients With Advanced Solid Tumors Harboring KRAS G12D Mutation TSN1611 - Malignant Neoplasm | Phase 1 / Phase 2 | Recruiting | Tyligand Pharmaceuticals (Suzhou) Limited | 440 | 2024-04-29 | 2026-04-24 |
| DETERMINE Trial Treatment Arm 01: Alectinib in Adult, Paediatric and Teenage/Young Adult Patients With ALK Positive Cancers Alectinib - Haematological Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-12-18 | 2025-11-24 |
| DETERMINE Trial Treatment Arm 02: Atezolizumab in Adult, Paediatric and Teenage/Young Adult Patients With Cancers With High Tumour Mutational Burden (TMB) or Microsatellite Instability-high (MSI-high) or Proven Constitutional Mismatch Repair Deficiency (CMMRD) Disposition Atezolizumab - Malignancy, Malignant Neoplasm | Phase 2 / Phase 3 | Recruiting | Cancer Research UK | 30 | 2023-10-25 | 2025-11-24 |
| A Study of OR502, a Monoclonal Antibody Targeting LILRB2, Alone and in Combination With Anticancer Agents OR502, Cemiplimab - Cancer, Tumor, Solid | Phase 1 / Phase 2 | Recruiting | OncoResponse, Inc. | 168 | 2023-10-24 | 2025-01-07 |
| NBM-BMX Administered Orally to Patients With Solid Tumors or Newly Diagnosed Glioblastoma NBM-BMX Capsule, Temozolomide, Standard radiotherapy - Malignant Neoplasm, Malignant Neoplasm of Brain | Phase 1 / Phase 2 | Recruiting | Novelwise Pharmaceutical Corporation | 79 | 2023-08-11 | 2026-04-29 |
| Intraoperative Tumor Margin Identification With ICG Dye Imaging Indocyanine green, SPY-PHI - Benign Neoplasm, Malignant Neoplasm | Phase 2 | Recruiting | Massachusetts General Hospital | 100 | 2022-05-25 | 2026-04-24 |
| Phase 2 Basket Trial of Nab-sirolimus in Patients With Malignant Solid Tumors With Pathogenic Alterations in TSC1/TSC2 Genes (PRECISION 1) nab-sirolimus - Tumor, Tumor, Solid | Phase 2 | Completed | Aadi Bioscience, Inc. | 128 | 2022-03-10 | 2026-10-28 |
Showing 20 of 45. Sign in to see all of them.
Neoplasms (45) · Neoplasms by Histologic Type (5) · Neoplasms by Site (5) · Carcinoma, Non-Small-Cell Lung (4) · Glioma (4) · Hematologic Neoplasms (4) · Lymphoproliferative Disorders (4) · Melanoma (4) · Brain Neoplasms (3) · Colorectal Neoplasms (3) · Lymphoma (3) · Multiple Myeloma (3) · Neoplasm Metastasis (3) · Carcinoma, Merkel Cell (2) · Dyspnea (2)
Hemic and Lymphatic Diseases (10) · Neoplasms, Germ Cell and Embryonal (10) · Neoplasms, Nerve Tissue (10) · Neuroectodermal Tumors (10) · Immune System Diseases (9) · Lymphatic Diseases (9) · Neoplasms by Histologic Type (9) · Neoplasms, Glandular and Epithelial (9) · Immunoproliferative Disorders (8) · Pathological Conditions, Signs and Symptoms (8) · Carcinoma (7) · Digestive System Diseases (7) · Hematologic Diseases (7) · Neoplasms by Site (7) · Respiratory Tract Diseases (7)
Cyclophosphamide (3) · Dexamethasone (3) · Magnetic Resonance Spectroscopy (2) · Mycophenolic Acid (2) · Palonosetron (2) · Peripheral Blood Stem Cell Transplantation (2) · Tacrolimus (2) · Whole-Body Irradiation (2) · cemiplimab (2) · dexamethasone acetate (2) · fludarabine phosphate (2) · netupitant (2) · pembrolizumab (2) · 2-Propanol (1) · 2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole (1)
Merck Sharp & Dohme LLC (9) · M.D. Anderson Cancer Center (6) · Cancer Research UK (5) · National Cancer Institute (NCI) (4) · OncoResponse, Inc. (2) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (2) · Wake Forest University Health Sciences (2) · Aadi Bioscience, Inc. (1) · Biotheus Inc. (1) · Cancer Institute and Hospital, Chinese Academy of Medical Sciences (1) · Children's Oncology Group (1) · City of Hope Medical Center (1) · Fred Hutchinson Cancer Center (1) · Jonsson Comprehensive Cancer Center (1) · Massachusetts General Hospital (1)
United States (34) · United Kingdom (7) · South Korea (6) · Spain (6) · China (5) · Taiwan (5) · Chile (4) · France (4) · Netherlands (4) · Turkey (Türkiye) (4) · Belgium (3) · Denmark (3) · Israel (3) · Australia (2) · Brazil (2)
Matthew Krebs, Dr (4) · David Hui (3) · Ahmed Kaseb (1) · Antonio Ribas, MD, PhD (1) · Carlos Roldan (1) · Cindy Li (1) · Dolores Grosso, DNP, CRNP (1) · Dudley Hammon (1) · George Chen, MD (1) · Hong Zhao (1) · Joseph Bubalo (1) · Lillian Sung (1) · Manish Sharma (1) · Marco Mielcarek (1)
PMID 20837940, PMID 30304652, PMID 30573690, PMID 33289280, PMID 33388382, PMID 33929874, PMID 34926296, PMID 36087590, PMID 36324139, PMID 37800415, PMID 38662981, PMID 39279435, PMID 42018190, PMID 42402341
2025 (4), N01CM62202 (3), P30CA014599 (2), N01CM62201 (1), P30CA012197 (1), P30CA015704 (1), P30CA016672 (1), P30CA033572 (1), P30CA124435 (1), R01HL108307 (1), R21CA187500 (1), U01CA069852 (1), U10CA095861 (1), UG1CA189961 (1)